Can DNA injections restore sight?

Article

The injection of DNA into the optic nerve resulted in light perception vision in patients with no light perception and very low vision, according to Sunita Agarwal, MD.

The injection of DNA into the optic nerve resulted in light perception vision in patients with no light perception and very low vision, according to Sunita Agarwal, MD.

Dr Agarwal, from Agarwal's Group of Eye Hospitals, Chennai, India, reported on five patients who have been treated with DNA injections. The DNA was amplified to more than 100 µm by manipulation with an injection of a biotech product (MANA) that was added to the patients' plasma under a microscope.

"This formulation has the advantage of layering on the patient's DNA molecule and amplifying it from a 0.0001 µm particle of DNA in the blood to over 100 µm using MANA. It is not a chemical, pharmaceutical, or an animal product," she explained.

The DNA is picked up using a 5 µm cannula and loaded into a 10 µL syringe with a 33- or 36-gauge needle. The patients who have either no vision or very low vision received intrapapillary injections of the customized MANA through the pars plana into the optic nerve. Dr Agarwal first used this technique in animals a decade ago and progressed to patients five years ago.

Four patients had optic atrophy; three of these had no perception of light and one had hand movement vision near the face. The fifth patient had age-related macular degeneration. Patients were examined 30 minutes after the procedure, for the next 10 days, and one month after the procedure, according to Dr Agarwal.

Of the four cases of the optic nerve disorders, two improved from no light perception to perception of light. One patient remained the same as before the procedure. The patient with hand movement vision near the face progressed to 6/60 vision.

"Amazingly, patients who had had no light perception for a long period gained light perception within seconds and minutes following an injection into the optic nerve," she said. "These injections of DNA showed phenomenal results unparalleled in the history of ophthalmology."

 

Read

ASCRS 2008 meeting highlights.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.